We are live on ! Find out more
CERT icon

Certara

7.55 USD
+0.13
1.75%
At close Updated Sep 11, 4:00 PM EDT
Pre-market
After hours
7.55
0.00
0%
1 day
1.75%
5 days
-5.86%
1 month
-7.13%
3 months
43.26%
6 months
13.36%
Year to date
-13.62%
1 year
-30.86%
5 years
-79.13%
10 years
-80.17%
 

About: Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

Employees: 1,576

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 5.3%
Neutral 89.5%
Negative 5.3%
Neutral
Seeking Alpha
25 days ago
Cerrado Gold Inc. (CERT:CA) Q2 2026 Earnings Call Transcript
Cerrado Gold Inc. (CERT:CA) Q2 2026 Earnings Call Transcript
Cerrado Gold Inc. (CERT:CA) Q2 2026 Earnings Call Transcript
Neutral
Seeking Alpha
1 month ago
Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript
Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript
Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript
Neutral
MarketBeat
1 month ago
Certara Q2 Earnings Call Highlights
Certara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure and artificial intelligence strategy.
Certara Q2 Earnings Call Highlights
Negative
Zacks Investment Research
1 month ago
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
Neutral
GlobeNewsWire
1 month ago
Certara Reports Second Quarter 2026 Financial Results
Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its second quarter 2026 financial results.
Certara Reports Second Quarter 2026 Financial Results
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Neutral
GlobeNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Neutral
GlobeNewsWire
2 months ago
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
Neutral
GlobeNewsWire
2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Price charts implemented using Lightweight Charts™